CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer May 23, 2022 8:30am EDT
CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor May 13, 2022 8:00am EDT
CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species” Apr 12, 2022 8:30am EDT
CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program Mar 30, 2022 5:00pm EDT
CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab Jan 25, 2022 6:06pm EST
